- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Sangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational data | ||
| Di | Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential | ||
| Di | MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b | ||
| Di | Amgen rolls out phase 3 dosing plan for lead obesity candidate after midstage trial sees high discontinuation, vomiting rates | ||
| Di | Stuart sees dry eye disease drug fail phase 3 tear test, plans another study | ||
| Di | Investors sweet on Nektar as phase 2b eczema success doubles share price | ||
| Di | Royalty signs off on $2B to bankroll Revolution's RAS cancer drug's road to regulators | ||
| Mo | BrightGene tops Novo drug in diabetes ahead of Zepbound showdown | ||
| Mo | Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication | ||
| Mo | Leap expands layoffs to cover 75% of employees, scraps only clinical trial to save cash | ||
| Mo | Corxel, Sciwind post GLP-1 data as China's obesity push gathers pace | ||
| Mo | Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed | ||
| Mo | Exelixis' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock soaring | ||
| Mo | Otsuka pens $670M pact to point Harbour's preclinical T-cell engager to autoimmune disease | ||
| Mo | Novo's injectable amycretin yet to hit weight-loss plateau, suggesting Zepbound-beating potential | ||
| Mo | Vertex's remaining islet cell therapy reduces dangerously low blood sugar levels in phase 1/2 test | ||
| Fr | FDA blocks new clinical trials that ship cells from US to China | ||
| Fr | Syncona blames 'challenging' market for shift in biotech investment strategy | ||
| Fr | Prothena lays off 63% of employees in fallout from phase 3 amyloidosis drug fail | ||
| Fr | Industry 'deeply disappointed' as FDA puts cell and gene therapy chief on administrative leave | ||
| 18.06. | Zealand Pharma's GLP-1/GLP-2 candidate linked to 11.6% weight loss after 28 weeks | ||
| 18.06. | US accused of denying R&D grants for biotechs based on international investor links | ||
| 18.06. | Taxes, tariffs and interest rates hold key to biotech's future amid uncertain outlook: EY | ||
| 18.06. | Scholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trial | ||
| 18.06. | China's rapid rise creates 'heightened risks' for pharma: PwC |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .